November 14, 2024 10:56 AM EST
News Briefing

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

ENDPOINTS

Plus, news about Al­lo­gene, Telix, Cull­gen, Pul­ma­trix, Gilead, In­no­coll, Durect and Sen­sei:

Zai Lab’s $200M of­fer­ing: The Shang­hai-based drug­mak­er is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times